Exelixis (NASDAQ:EXEL) Q3 2023 Earnings Conference Call November 1, 2023 5:00 PM ET
Company Participants
Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations
Mike Morrissey - President and Chief Executive Officer
Chris Senner - Chief Financial Officer
PJ Haley - Executive Vice President, Commercial
Dana Aftab - Chief Scientific Officer
Amy Peterson - Chief Medical Officer
Conference Call Participants
Michael Schmidt - Guggenheim Partners
Jason Gerberry - Bank of America Merrill Lynch
Gregory Renza - RBC Capital Markets
Jay Olson - Oppenheimer and Company
Jing Deng - Truist
Andy Hsieh - William Blair and Company
Yaron Werber - TD Cowen
Silvan Tuerkcan - JMP Securities
Peter Lawson - Barclays
Jeff Hung - Morgan Stanley
Etzer Darout - BMO Capital Markets
Joe Catanzaro - Piper Sandler
Stephen Willey - Stifel Financial Corp.
Christopher Lyle - Leerink Partners
Operator
Good day, ladies and gentlemen, and welcome to the Exelixis Third Quarter 2023 Financial Results Conference Call. My name is Gigi, and I'll be your operator for today. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. Please proceed.
Susan Hubbard
Thank you, Gigi, and thank you all for joining us for the Exelixis third quarter 2023 financial results conference call. Joining me on today's call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; P.J. Haley, our Executive Vice President of Commercial; Amy Peterson, our Chief Medical Officer and Dana Aftab, our Chief Scientific Officer who will review our progress for the third quarter 2023 ended September 30, 2023. Peter Lamb, our EVP of Scientific Strategy, will join us for the Q&A portion of the call.
During the call today, we will refer to financial measures not calculated according to generally accepted accounting principles. Please refer to today's press release which is posted on our website for an explanation of our reasons for using such non-GAAP measures, as well as tables deriving those measures from our GAAP results. During the course of this presentation, we will be making forward-looking statements regarding future events and the future performance of the company. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial, and strategic matters.
Actual events or results could of course differ materially. We refer you to the documents we filed from time to time with the SEC, which under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed by the company verbally and in writing today, including without limitation, risks and uncertainties related to product commercial success, market competition, regulatory review, and approval processes, conducting clinical trials, compliance with applicable regulatory requirements, our dependence on collaboration partners, and the level of costs associated with discovery, product development, business development and commercialization activities. And with that, I will turn the call over to Mike.